PepGen Inc. (NASDAQ:PEPG) Insider Michelle L. Mellion Sells 12,625 Shares

PepGen Inc. (NASDAQ:PEPG) insider Michelle L. Mellion sold 12,625 shares of the business’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $18.20, for a total transaction of $229,775.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michelle L. Mellion also recently made the following trade(s):

• On Friday, July 12th, Michelle L. Mellion sold 3,288 shares of PepGen stock. The stock was sold at an average price of $18.04, for a total transaction of $59,315.52.
• On Tuesday, July 16th, Michelle L. Mellion sold 5,901 shares of PepGen stock. The stock was sold at an average price of $18.00, for a total transaction of $106,218.00.
• On Tuesday, July 2nd, Michelle L. Mellion sold 37 shares of PepGen stock. The stock was sold at an average price of $18.07, for a total transaction of $668.59.
• On Monday, June 24th, Michelle L. Mellion sold 9,260 shares of PepGen stock. The stock was sold at an average price of $18.19, for a total transaction of $168,439.40.
• On Tuesday, June 11th, Michelle L. Mellion sold 500 shares of PepGen stock. The stock was sold at an average price of $18.04, for a total transaction of $9,020.00.

PepGen Trading Down 0.4 %

Shares of NASDAQ:PEPG opened at $16.55 on Monday. The company has a market capitalization of $536.50 million, a price-to-earnings ratio of -5.09 and a beta of 1.73. PepGen Inc. has a 12 month low of $3.72 and a 12 month high of $18.72. The firm’s 50-day moving average is $16.25 and its 200 day moving average is $13.60.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.11. As a group, equities analysts forecast that PepGen Inc. will post -2.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of PepGen in a report on Wednesday, May 15th. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of PepGen in a report on Wednesday, May 15th.

Hedge Funds Weigh In On PepGen

Several hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in PepGen during the 1st quarter valued at about $30,000. Janus Henderson Group PLC boosted its position in PepGen by 18.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after buying an additional 178,438 shares during the period. Artal Group S.A. purchased a new stake in PepGen in the 1st quarter valued at about $2,940,000. Vanguard Group Inc. boosted its position in PepGen by 68.0% in the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock valued at $12,502,000 after buying an additional 344,266 shares during the period. Finally, RA Capital Management L.P. boosted its position in PepGen by 31.5% in the 1st quarter. RA Capital Management L.P. now owns 10,689,545 shares of the company’s stock valued at $157,136,000 after buying an additional 2,557,593 shares during the period. 58.01% of the stock is currently owned by institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.